Although not a Parkinson's study, the reported CAR-T–associated Parkinsonism is a clinically relevant signal that may inform immune- or cytokine-mediated mechanisms of basal ganglia dysfunction and could guide safety monitoring, modeling, or repurposing studies related to immune-driven parkinsonism.

Intranasal ethosomes could enable noninvasive, targeted delivery of Parkinson's therapeutics (e.g., neuroprotective agents or biologics) to the brain and reduce systemic exposure, but translation is limited by safety concerns and lack of clinical validation.

Offers a practical, patient-friendly delivery platform that could noninvasively improve bioavailability and enable sustained or targeted delivery of neuroprotective agents for Parkinson's disease—bridging a translational gap—though payload capacity, consistent skin penetration, and scalable…

Supports the repurposing of GLP-1 receptor agonists as candidate neuroprotective therapies for Parkinson's disease with high translational potential given existing clinical safety data, though causality requires randomized trials and mechanistic studies to confirm.

By uncovering a mechanistic, potentially actionable route (iron-modulated antimicrobial effects of COMT‑Is) that impacts L‑DOPA metabolism, the work suggests opportunities to predict or mitigate variable patient responses to co‑prescribed Parkinson’s medications via microbiome profiling or targeted…

This study provides translationally actionable evidence that spermidine supplementation can modulate peripheral immunity to alleviate PD-relevant non-motor symptoms, supporting repurposing and biomarker-guided clinical investigation.

Positions SERPING1 as a modifiable inflammatory/complement-related target that reduces α-syn pathology and neurodegeneration in vivo, offering actionable therapeutic and repurposing opportunities (but requiring validation of delivery, mechanism, and safety).

Provides mechanism-anchored genetic support that GLP1R-mediated pathways influence PDRD risk, strengthening rationale for GLP-1RA repurposing and for incorporating GLP1R-expression–based stratification or biomarkers into future Parkinson's prevention and therapeutic trials.

Highlights imaging-accessible mechanisms—neuroinflammation, mitochondrial dysfunction, and glutamatergic dysregulation—that overlap with Parkinson's-relevant biology and could inform biomarker-driven target selection, patient stratification, or repurposing strategies for PD therapeutic discovery.

Provides a clinically accessible autophagy–immune linked biomarker panel with modest diagnostic performance and nominates mechanistically relevant genes (autophagy/lysosomal and immune-related) for follow-up as potential therapeutic targets or stratification tools, though prospective validation and…

This work presents a translational drug‑delivery approach that could repurpose an approved MAO‑B inhibitor for more consistent, minimally invasive dosing and potential symptomatic neuroprotection, though therapeutic novelty is limited and findings are restricted to animal data without deep…

While not mechanistic, the finding that CAR-T therapy can produce rare parkinsonism cases points to immune-mediated or neuroinflammatory routes to parkinsonism and is useful for surveillance and hypothesis generation for translational studies exploring inflammation-driven or iatrogenic PD…

By defining a specific circuit and receptor (STN D2) that can be targeted to reduce Parkinsonian and neuropathic mechanical pain, the work provides an actionable mechanistic target with translational potential for repurposing D2-directed therapies or developing focal neuromodulation strategies for…

Presents a non‑invasive neuromodulation approach that modulates cortico‑subthalamic circuits and shows potential symptomatic benefit and dopaminergic marker enhancement, making it a promising translational lead for PD therapy pending mechanistic clarification and long‑term validation.

Provides early-stage in vivo evidence of a neuroprotective compound that rescues dopaminergic deficits linked to mitochondrial toxin exposure, making it a promising candidate for follow-up mechanistic studies and mammalian translational work.

By creating a pathology-anchored, AI-enhanced noninvasive imaging biomarker for early PD staging, this approach could improve patient stratification and trial enrollment—boosting translational and diagnostic value even though it does not directly probe molecular therapeutic mechanisms.

Provides preliminary evidence that an agri-food polyphenol-rich extract has dopaminergic neuroprotective effects and could be a source of candidate bioactive compounds for PD discovery, but requires mechanistic studies, compound isolation, and translational testing in mammalian models.

While the method could enhance diagnostic decision-support and early detection, it offers minimal mechanistic, biomarker, or therapeutic actionable insight for Parkinson's drug discovery or translational intervention development.

Identifies DYRK1A as a convergent, druggable kinase connecting multiple PD-relevant mechanisms and supports further preclinical evaluation and repurposing of DYRK1A modulators as potential neuroprotective therapies.

The extract's anti‑inflammatory and antioxidant effects are conceptually relevant to Parkinson's disease neuroinflammation and the Mucuna genus is a known L‑DOPA source, but absence of CNS, dopaminergic neuron, alpha‑synuclein, pharmacokinetic or PD‑model data limits immediate translational value…

Highlights a translational delivery approach that could substantially boost brain bioavailability and reduce systemic toxicity for PD drugs, making it a useful roadmap for advancing therapies if key nasal formulation and clinical testing barriers are solved.

For Parkinson's research, BDCD enables hypothesis-driven identification of disease-relevant intercellular signaling pathways, prioritization of genetically linked ligand–receptor axes, and nomination of drug repurposing or target-modulation opportunities with spatial and cell-type resolution.

Provides experimental in vivo support that HLA genotype modulates alpha-synuclein pathology, highlighting an immune-genetic mechanism that could inform patient stratification, biomarker development, and immune- or microglia-directed therapeutic strategies for PD.

Offers preclinical evidence that IL-6 signaling can be neuroprotective in PD and highlights recombinant IL-6 or modulation of IL-6 pathways—as well as sex-specific responses—as actionable avenues for therapeutic development, albeit with translational cautions around cytokine pleiotropy and systemic…

Moderate therapeutic relevance: the work links noninvasive imaging (SNH) with inflammation and homocysteine pathways, offering a stratification tool for trials and pointing to actionable avenues (anti‑inflammatory, Hcy‑lowering, iron‑modulating strategies), though it remains a…